Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions David Burrows
Amgen Inc.AMGNBUYOct 10, 2013
David BurrowsOwned
$109.92
Stock price when the opinion was issued
$336.13
As of Jun 18, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
BUY
BUY
He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.
biotechnologypharmaceutical
TOP PICK
Granddaddy of biotech. Even better than it used to be. Very deep bench of drugs. New acquisition will add growth on top of already-decent growth. Very strong financials. Income opportunity, stability, and some growth not yet fully priced in. Yield is 3.14%, well covered at 42%, increased by 11% average annually over 5 years. (Analysts’ price target is $268.80)
Gordon ReidOwned
biotechnologypharmaceutical
BUY
Today, they said they are buying Horizon Therapeutics for $27.8 billion. This deal should close quickly, since there's little overlap of these companies' drugs. Initially, he thought the price was high, but now he likes the deal. An established, big biotech that bought a younger biotech with exciting drugs at a 15% premium. Amgen wants HT's portfolio of drugs treating rare diseases and well-covered by insurance, therefore lucrative. HT's drugs will benefit from Amgen's worldwide distribution.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
Andrew PyleOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
Andrew PyleOwned
biotechnologypharmaceutical
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
BUY
Some of their key drugs are coming off patent, so he likes how they're making key buys of companies like CCXI, which would give Amgen exposure to drugs for auto-immune diseases and inflammatory conditions. CCXI has one drug on the market to treat blood vessel inflammation and a handful of phase 1 treatments including ulcerative colitis. The deal is good for Amgen.
biotechnologypharmaceutical
Premium contentPAST TOP PICK
The healthcare space is leading the market. This is a little more aggressive. XBI, an ETF is an alternative. Consolidation is taking place in the Pharma space. AMGN should continue to return cash to shareholders. It is probably not a buyout target.